Compare CMPX & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMPX | MNKD |
|---|---|---|
| Founded | 2014 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 927.5M | 877.0M |
| IPO Year | 2020 | 2004 |
| Metric | CMPX | MNKD |
|---|---|---|
| Price | $1.91 | $3.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $14.57 | $8.69 |
| AVG Volume (30 Days) | ★ 10.8M | 3.3M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | N/A | $35.81 |
| Revenue Next Year | $934.41 | $11.89 |
| P/E Ratio | ★ N/A | $142.75 |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $1.61 | $2.23 |
| 52 Week High | $6.88 | $6.51 |
| Indicator | CMPX | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 24.24 | 74.20 |
| Support Level | $1.61 | $3.39 |
| Resistance Level | $3.63 | $6.21 |
| Average True Range (ATR) | 0.38 | 0.18 |
| MACD | -0.26 | 0.09 |
| Stochastic Oscillator | 5.04 | 58.53 |
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.